Livagen (KEDA; Lys-Glu-Asp-Ala): mechanism, evidence and research limits

Livagen, also rendered Lyvagen in one paper, is a defined synthetic tetrapeptide: Lys-Glu-Asp-Ala (one-letter sequence KEDA). It is therefore actually a peptide, not a hormone, small molecule, liver extract or multi-ingredient blend. The evidence located is laboratory, animal and ex-vivo human-cell work; it should be treated as a research substance, not as an established Australian therapeutic formulation.

Livagen is a four-amino-acid synthetic peptide studied mainly by a small, overlapping body of literature. In isolated human serum it inhibited enkephalin-degrading activity; in cultured lymphocytes from older donors it was associated with chromatin decondensation measures; and in rat hepatocyte cultures it increased protein-synthesis measurements. These are model-specific findings, not proof of liver repair, anti-ageing benefit or clinical safety in people. The reviewed sources provide no validated human dosing, injection, dilution, storage or treatment schedule.

Livagen is the name used in the literature for the tetrapeptide Lys-Glu-Asp-Ala (KEDA). A rat-hepatocyte paper describes it as produced by directed chemical synthesis based on amino-acid analysis of liver polypeptide preparations. That origin story does not make KEDA a liver extract: the experimental substance is a specified four-residue peptide. It is also distinct from Epitalon/Epithalon, whose sequence is Ala-Glu-Asp-Gly. [1] [3]

The most defensible classification is a synthetic, research-stage peptide bioregulator. It is not a glycoprotein hormone, not a topical cosmetic ingredient and not a small molecule. Names on supplier vials do not themselves establish identity, sterility, concentration, clinical quality or approval; product-specific evidence must come from the actual manufacturer and regulator record. [3] [7]

The located record is narrow. It includes an in-vitro human-serum/radioreceptor experiment, cultured lymphocytes from older people, primary rat hepatocyte cultures, and rat gastrointestinal-enzyme work. These are useful for generating hypotheses, but they do not test whether Livagen prevents, treats or reverses liver disease in patients. [1] [2] [3] [4] [5]

Several publications come from closely connected authors or institutions and some full reports are in Russian with only English abstracts readily indexed. A 2020 paper indexed as a review summarises animal and in-vitro liver-pathology literature rather than reporting a new randomised human efficacy trial. That combination limits independent replication and makes broad health claims premature. [3] [9]

Kost and colleagues tested Livagen in isolated human serum by measuring hydrolysis of radiolabelled Leu-enkephalin. In that assay, Livagen inhibited enkephalin-degrading activity with a reported IC50 of 20 micromolar; the same report found no interaction with mu or delta opioid receptors in rat brain membrane fractions using its radioreceptor method. This supports an assay-specific enzyme observation, not an opioid-like effect in a person. [1]

A chromatin mechanism is often asserted much more strongly than the data allow. In cultured lymphocytes from older donors, investigators reported greater ribosomal-gene activity and changes described as deheterochromatinisation or decondensation of selected chromatin regions after Livagen exposure. The studies did not establish a direct DNA-binding mechanism, identify a clinical target tissue, or show that these cellular readouts improve health outcomes. [2] [4] [6]

The clearest liver-specific primary experiment located used monolayer cultures of hepatocytes from rats aged 1 to 24 months. Livagen increased measured protein synthesis across ages, with the largest reported effect in cells from older rats; it also increased the amplitude of protein-synthesis fluctuations in hepatocytes from old rats. The comparator tetrapeptide Epitalon did not change protein-synthesis intensity in that culture system. [3]

Those results cannot be converted into a claim that Livagen regenerates a human liver. Isolated rat hepatocytes lack the circulation, immune system, fibrosis architecture, disease causes and clinical endpoints of a person with hepatitis, cirrhosis or drug-induced liver injury. The later review's favourable account of animal and in-vitro hepatitis/fibrosis models is background literature, not substitute evidence for a controlled clinical trial. [3] [9]

The human-linked reports found are ex-vivo/cultured-cell studies, not clinical treatment trials. One 2002 report examined lymphocytes from older people, and a 2004 study examined leukocytes from subjects aged 75–88 years; both reported chromatin-related laboratory changes after short-peptide exposure. Neither abstract reports patient-centred outcomes such as symptoms, liver function, hospitalisation, longevity or quality of life. [2] [4]

Accordingly, there is no evidence-grounded human administration schedule to report. The located literature does not establish a therapeutic route, dose, course length, reconstitution method, shelf-life, interaction profile, pregnancy safety, or long-term safety monitoring plan for Livagen in people. Absence of those data is a safety and evidence gap, not permission to infer them from a research vial. [1] [2] [3] [4] [5] [6]

The rat gastrointestinal study reported that small-intestinal peptide hydrolases did not hydrolyse Livagen to an appreciable extent in its experiment and that two weeks of oral administration altered digestive-enzyme activity differently in young and old rats. These findings do not establish human absorption, bioavailability, organ exposure or safety, but they reinforce that metabolism should be measured rather than assumed. [5]

For unapproved peptide products generally, the TGA warns that safety, quality and effectiveness may not have been evaluated and that important information can be unknown, including manufacture, sterility, ingredients, adverse effects and interactions. Injection adds contamination, infection and local-tissue risks. This is a product-category warning, not a Livagen-specific adverse-event rate. [7]

The ARTG is the TGA's public database for therapeutic goods that can be legally supplied in Australia, and it can be searched by product name and active ingredient. This review did not locate an ARTG product, Australian Product Information, Consumer Medicine Information or AusPAR for Livagen/KEDA; that is a limited search finding, not a regulator determination. A prospective user or clinician should repeat the live ARTG search using both names and examine the exact sponsor and formulation. [8]

The TGA states that unapproved peptide products have not been evaluated by it for safety, quality or effectiveness, and that a ‘research use only’ disclaimer does not itself change regulatory status or make importation/supply lawful. Compounding and individual access are regulated pathways with conditions; they do not validate a commercially promoted Livagen vial or its claims. [7] [8]

Keep the level of evidence attached to the outcome. ‘Inhibited an enzyme in human serum’ is not the same claim as ‘modulates endogenous opioids in patients’; ‘increased protein synthesis in cultured rat hepatocytes’ is not ‘repairs the liver’; and a change in lymphocyte chromatin microscopy is not evidence of anti-ageing benefit. The outcome, model and comparator should appear together whenever this research is described. [1] [2] [3] [4]

Comparisons with other short peptides should also stay sequence- and model-specific. Livagen and Epitalon are both tetrapeptides, but their sequences differ and the rat-hepatocyte culture study reported a protein-synthesis effect for Livagen, not Epitalon. This does not demonstrate clinical superiority of either compound and does not support combining them. No validated combined protocol was located. [1] [3]

Is Livagen actually a peptide?

Yes. Livagen/KEDA is the four-amino-acid synthetic peptide Lys-Glu-Asp-Ala. It is not a hormone, a liver extract or a mixture. [1] [3]

Is Livagen an approved liver medicine in Australia?

No ARTG product record or Australian product-information document for Livagen/KEDA was located in this review. Because the ARTG is the live public register, status should be verified there by exact product and active-ingredient name before relying on any claim. [8]

Has Livagen been shown to repair the human liver?

No. The liver-specific primary result located was increased protein-synthesis measurement in cultured rat hepatocytes. It is not a human liver-disease outcome. A later review discusses animal and in-vitro models, not a new controlled clinical efficacy trial. [3] [9]

What human research has been published?

The located human-linked work concerns cultured lymphocytes/leukocytes from older donors, including subjects aged 75–88 years, and chromatin-related laboratory endpoints. It does not establish clinical benefit or a safe treatment regimen. [2] [4] [6]

Can online research-vial instructions be used as a dosing guide?

No. The reviewed studies do not validate human dose, route, reconstitution, storage or treatment duration. The TGA also cautions that ‘research use only’ does not determine legal status and that unapproved peptide products can have unknown quality and safety. [1] [2] [3] [4] [5] [6] [7]

This is a deliberately evidence-limited record: the accessible Livagen literature located was mainly older laboratory, animal and ex-vivo work, often available only as English abstracts of Russian-language reports. Several papers have overlapping investigators or institutions, and no controlled human clinical outcome study was located in this review. [1] [2] [3] [4] [5] [6] [9]

A negative ARTG search performed during research is not proof that no lawful pathway or product can ever exist; register entries, exemptions and sponsor details can change. The ARTG should be checked live for the exact product, formulation and sponsor. [8]

1. [1] Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. In-vitro human-serum enkephalinase assay and rat-brain membrane radioreceptor binding experiment.
2. [2] Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Cultured lymphocytes from older people assessed for ribosomal genes and chromatin/heterochromatin measures after Livagen exposure.
3. [3] Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Monolayer hepatocyte cultures from rats aged 1–24 months; protein-synthesis rhythm measured with Livagen and Epitalon comparison.
4. [4] Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects. Leukocyte study in subjects aged 75–88 years comparing several short peptides on ribosomal genes and chromatin measures.
5. [5] Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. In-vitro small-intestinal enzyme experiment plus two-week oral administration in young and old rats.
6. [6] Anti-aging peptide bioregulators induce reactivation of chromatin. Cultivated lymphocytes from people aged 75–88 years studied with Epitalon, Livagen and Vilon.
7. [7] Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. TGA regulatory and safety guidance; not a Livagen clinical study.
8. [8] About the Australian Register of Therapeutic Goods (ARTG). TGA explanation of the public therapeutic-goods register and access pathways.
9. [9] The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Review of animal and in-vitro liver-pathology literature concerning a calf-liver polypeptide complex and KEDA/Livagen.